<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2629">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333589</url>
  </required_header>
  <id_info>
    <org_study_id>2020 research 112</org_study_id>
    <nct_id>NCT04333589</nct_id>
  </id_info>
  <brief_title>Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive</brief_title>
  <official_title>The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the mechanism, clinical outcome and therapeutic efficacy with favipiravir of
      Corona Virus Disease 2019 patients whose nucleic acids changed from negative to positive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinical institutions that enroll corona virus disease 2019 patients whose nucleic acids
      changed from negative to positive, two arms, multi-center, randomized and controlled methods
      are adopted. Patients are divided into two groups, favipiravir group and regular treatment
      group. 210 patients are expected to be enrolled and the cases are allocated according to the
      ratio of 2( favipiravir group): 1(regular treatment group).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral nucleic acid test negative conversion rate</measure>
    <time_frame>5 months</time_frame>
    <description>Proportion of subjects who tested negative for nucleic acid from sputum or nasopharyngeal swabs for two consecutive times(sampling time at least 24 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>5 months</time_frame>
    <description>Definition of clinical cure: The viral load of the respiratory specimen was negative for two consecutive times (the interval between the two tests was greater than or equal to one day), the lung image improved, and the body temperature returned to normal for more than 3 days, and the clinical manifestation improved.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Favipiravir group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.</description>
    <arm_group_label>Favipiravir group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. COVID-19 has been diagnosed, and the nucleic acid test of respiratory specimens such
             as sputum or nasopharyngeal swabs has been negative for two consecutive times after
             treatment (sampling time interval of at least 24 hours);

          2. The nucleic acid test of specimens such as sputum, throat swabs, blood, feces and
             other specimens was positive for COVID-19 during screening visits;

          3. Voluntarily participate in research and sign informed consent.

        Exclusion Criteria:

          1. Those allergic to fapilavir;

          2. Pregnant or lactating women;

          3. Unstable liver, kidney, and heart diseases;

          4. History of mental disorders, substance abuse or dependence;

          5. Researchers consider it inappropriate to participate in research;

          6. Participating in other clinical research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqiang Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiqiang Wang</last_name>
    <phone>13911405123</phone>
    <email>john131212@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Zhao</last_name>
    <phone>13810765943</phone>
    <email>zhaohong_pufh@bjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second People's Hospital of Fuyang</name>
      <address>
        <city>Fuyang</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianfeng Han</last_name>
      <phone>13955881280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ezhou Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Ezhou</city>
        <state>Hubei</state>
        <zip>436000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinsheng Chen</last_name>
      <phone>13972975677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ezhou Central Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junhua Yu</last_name>
      <phone>13908688619</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huoshenshan Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sibin Zhang</last_name>
      <phone>13911992121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinyintan Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingyu Zhang</last_name>
      <phone>13507117929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Pulmonary Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianxiang Chen</last_name>
      <phone>18971570937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinghuan Wang</last_name>
      <phone>18971387168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenzhou Medical University Affiliated First Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongping Chen</last_name>
      <phone>13505777281</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Guiqiang Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Favipiravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

